Sarepta Therapeutics’ (SRPT) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report released on Thursday, MarketBeat.com reports. They currently have a $50.00 target price on the biotechnology company’s stock.

A number of other brokerages also recently weighed in on SRPT. Bank of America reissued a “neutral” rating and issued a $28.00 price target (down from $76.00) on shares of Sarepta Therapeutics in a report on Monday, June 16th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Sarepta Therapeutics from $50.00 to $25.00 and set a “hold” rating for the company in a research note on Tuesday, June 17th. TD Cowen cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $24.00 target price for the company. in a research report on Wednesday, June 18th. Jefferies Financial Group decreased their price objective on shares of Sarepta Therapeutics from $125.00 to $54.00 and set a “buy” rating on the stock in a report on Monday, June 16th. Finally, Piper Sandler lowered shares of Sarepta Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $70.00 to $36.00 in a report on Monday, June 16th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Hold” and an average price target of $56.50.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $14.07 on Thursday. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -5.23 and a beta of 0.45. Sarepta Therapeutics has a 12 month low of $12.81 and a 12 month high of $150.48. The firm has a 50 day moving average of $28.42 and a two-hundred day moving average of $67.97.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. Sarepta Therapeutics’s quarterly revenue was up 80.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.73 earnings per share. As a group, equities analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Capital International Investors raised its holdings in shares of Sarepta Therapeutics by 38.9% in the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares during the last quarter. Norges Bank bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $126,315,000. Assenagon Asset Management S.A. boosted its position in shares of Sarepta Therapeutics by 438.0% in the first quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company’s stock valued at $45,477,000 after acquiring an additional 580,123 shares during the period. Wellington Management Group LLP raised its stake in Sarepta Therapeutics by 27.9% in the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock valued at $168,907,000 after purchasing an additional 577,848 shares in the last quarter. Finally, EcoR1 Capital LLC raised its stake in Sarepta Therapeutics by 67.8% in the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company’s stock valued at $82,480,000 after purchasing an additional 522,386 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.